Chemical and molecular basis of the carcinogenicity of Aristolochia plants

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 1, 2009, Pages 141-148

  Schmeiser, H H ^a   Stiborova M ^b   Arlt, V M ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Aristolochia; Aristolochic acid; Aristolochic acid nephropathy (AAN); Balkan endemic nephropathy (BEN); Carcinogenesis; Urothelial cancer

Indexed keywords

7 (DEOXYADENOSIN N6 YL)ARISTOLACTAM; ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I; ARISTOLOCHIC ACID II; MUTAGENIC AGENT; NITROPHENANTHRENE CARBOXYLIC ACID; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARISTOLOCHIA; ARISTOLOCHIC ACID NEPHROPATHY; AUTORADIOGRAPHY; BALKAN ENDEMIC NEPHROPATHY; CARCINOGENICITY; CHEMICAL COMPOSITION; CHINESE MEDICINE; DNA ADDUCT; DRUG METABOLISM; DRUG STRUCTURE; GENOTOXICITY; HUMAN; LIQUID CHROMATOGRAPHY; METABOLIC ACTIVATION; MUTATION; NEPHROTOXICITY; NONHUMAN; ONCOGENE RAS; REVIEW; TANDEM MASS SPECTROMETRY; UROGENITAL TRACT TUMOR;

ANIMALS; ARISTOLOCHIA; ARISTOLOCHIC ACIDS; CARCINOGENICITY TESTS; CARCINOGENS; DNA ADDUCTS; HUMANS; MOLECULAR STRUCTURE; UROLOGIC NEOPLASMS;

EID: 58449131001     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. World Health Organization - International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. IARC Press, Lyon, France (2002).
2. National Toxicology Program: National Toxicology Program, Research Triangle Park, NC, USA (2008). http://ntp.niehs.nih.gov/files/ AAPanelReportBSciJustFinal-508.pdf
3. Mengs U, Lang W, Poch JA: The carcinogenic action of aristolochic acid in rats. Arch Toxicol (1982) 51(2):107-119.
4. Debelle FD, Vanherweghem JL, Nortier JL: Aristolochic acid nephropathy: A worldwide problem. Kidney Int (2008) 74(2):158-169.
5. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M: Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet (1993) 341(8842):387-391. • First report on AAN.
6. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL: Identification of aristolochic acid in Chinese herbs. Lancet (1994) 343(8890):174.
7. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP: Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res (1996) 56(9):2025-2028. • Reports the first detection of specific AA-DNA adducts in humans.
8. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis (1997) 18(5):1063-1067.
9. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, etein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL: Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med (2000) 342(23):1686-1692. •• Provides strong evidence that AA is the causal factor for AAN and AAN-associated urothelial cancer.
10. Gillerot G, Jadoul M, Arlt VM, van Ypersele De Strihou C, Schmeiser HH, But PP, Bieler CA, Cosyns JP: Aristolochic acid nephropathy in a Chinese patient: Time to abandon the term "Chinese herbs nephropathy"? Am J Kidney Dis (2001) 38(5):E26.
11. Schwetz BA: From the Food and Drug Administration. JAMA (2001) 285(21):2705.
12. Schmeiser HH, Janssen JW, Lyons J, Scherf HR, Pfau W, Buchmann A, Bartram CR, Wiessler M: Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res (1990) 50(17):5464-5469.
13. Cui M, Liu ZH, Qiu Q, Li H, Li LS: Tumour induction in rats following exposure to short-term high dose aristolochic acid I. Mutagenesis (2005) 20(1):45-49.
14. Qiu Q, Liu ZH, Chen HP, Yin HL, Li LS: Long-term outcome of acute renal injury induced by Aristolochia manshuriensis Kom in rats. Acta Pharmacol Sin (2000) 21(12):1129-1135.
15. Hwang MS, Park MS, Moon JY, Lee JS, Yum YN, Yoon E, Lee H, Nam KT, Lee BM, Kim SH, Yang KH: Subchronic toxicity studies of the aqueous extract of Aristolochiae fructus in Sprague-Dawley rats. J Toxicol Environ Health A (2006) 69(24):2157-2165.
16. Cosyns JP, Goebbels RM, Liberton V, Schmeiser HH, Bieler CA, Bernard AM: Chinese herbs nephropathy-associated slimming regimen induces tumors in the forestomach but no interstitial nephropathy in rats. Arch Toxicol (1998) 72(11):738-743.
17. Stiborová M, Frei E, Arlt VM, Schmeiser HH: Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res (2008) 658(1-2):55-67.
18. Chan W, Luo HB, Zheng Y, Cheng YK, Cai Z: Investigation of the metabolism and reductive activation of carcinogenic aristolochic acids in rats. Drug Metab Dispos (2007) 35(6):866-874.
19. Schmeiser HH, Pool BL, Wiessler M: Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimurium. Cancer Lett (1984) 23(1):97-101.
20. Götzl E, Schimmer O: Mutagenicity of aristolochic acids (I, II) and aristolic acid I in new YG strains in Salmonella typhimurium highly sensitive to certain mutagenic nitroarenes. Mutagenesis (1993) 8(1):17-22.
21. Purohit V, Basu AK: Mutagenicity of nitroaromatic compounds. Chem Res Toxicol (2000) 13(8):673-692.
22. Arlt VM, Stiborovà M, Schmeiser HH: Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis (2002) 17(4):265-277.
23. 32P-postlabeling assay for DNA adducts. Nat Protoc (2007) 2(11):2772-2782.
24. Chan W, Zheng Y, Cai Z: Liquid chromatography-tandem mass spectrometry analysis of the DNA adducts of aristolochic acids. J Am Soc Mass Spectrom (2007) 18(4):642-650.
25. Stiborová M, Frei E, Schmeiser HH: Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int (2008) 73(11):1209-1211.
26. 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab Dispos (2006) 34(7):1122-1127.
27. Schmeiser HH, Scherf HR, Wiessler M: Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice. Cancer Lett (1991) 59(2):139-143.
28. Cheng CL, Chen KJ, Shih PH, Lu LY, Hung CF, Lin WC, Yesong Gu J: Chronic renal failure rats are highly sensitive to aristolochic acids, which are nephrotoxic and carcinogenic agents. Cancer Lett (2006) 232(2):236-242.
29. Kohara A, Suzuki T, Honma M, Ohwada T, Hayashi M: Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (MutaMouse). Mutat Res (2002) 515(1-2):63-72.
30. Mei N, Arlt VM, Phillips DH, Heflich RH, Chen T: DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat Res (2006) 602(1-2):83-91.
31. Chen L, Mei N, Yao L, Chen T: Mutations induced by carcinogenic doses of aristolochic acid in kidney of Big Blue transgenic rats. Toxicol Lett (2006) 165(3):250-256.
32. 32P-postlabelling in target and non-target organs of rats treated with aristolochic acid I. IARC Sci Publ (1993) (124):167-171.
33. Broschard TH, Wiessler M, von der Lieth CW, Schmeiser HH: Translesional synthesis on DNA templates containing site-specifically placed deoxyadenosine and deoxyguanosine adducts formed by the plant carcinogen aristolochic acid. Carcinogenesis (1994) 15(10):2331-2340.
34. Cosyns JP: Aristolochic acid and "Chinese herbs nephropathy": A review of the evidence to date. Drug Safety (2003) 26(1):33-48.
35. Arlt VM, Pfohl-Leszkowicz A, Cosyns JP, Schmeiser HH: Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy. Mutat Res (2001) 494(1-2):143-150.
36. Nortier JL, Schmeiser HH, Muniz Martinez MC, Arlt VM, Vervaet C, Garbar CH, Daelemans P, Vanherweghem JL: Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure. Nephrol Dial Transplant (2003) 18(2):426-428.
37. Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD: Urothelial malignancy and Chinese herbal nephropathy. Lancet (2001) 358(9292):1515-1516.
38. 32P-postlabeling are derived from AA and that mutations typical for AA are found in BEN patients, thereby establishing AA as a risk factor for BEN and BEN-associated urothelial cancer.
39. Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, Schmeiser HH: DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis (2004) 43(4):e11-e17. • Reports the first detection of a mutation typical for AA in an AAN patient.
40. Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M: Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci USA (2004) 101(9):2963-2968.
41. Feldmeyer N, Schmeiser HH, Muehlbauer KR, Belharazem D, Knyazev Y, Nedelko T, Hollstein M: Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat Res (2006) 608(2):163-168.
42. Vanherweghem LJ: Misuse of herbal remedies: The case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J Altern Complement Med (1998) 4(1):9-13.
43. Schulz WA, Krummeck A, Rösinger I, Eickelmann P, Neuhaus C, Ebert T, Schmitz-Dräger BJ, Sies H: Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics (1997) 7(3):235-239.
44. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D: NAD(P) H:quinone oxidoreductase (NQO1): Chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact (2000) 129(1-2):77-97.
45. Arlt VM, Stiborová M, vom Brocke J, Simões ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH: Aristolochic acid mutagenesis: Molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis (2007) 28(11):2253-2261.
46. Ivić M: [Etiology of endemic nephropathy] Lijec Vjesn. (1969) 91(12):1273-1281.
47. Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, Jelaković B: Endemic nephropathy: The case for chronic poisoning by aristolochia. Croat Med J (2005) 46(1):116-125.
48. Arlt VM, Ferluga D, Stiborovà M, Pfohl-Leszkowicz A, Vukelic M, Ceovic S, Schmeiser HH, Cosyns JP: Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer (2002) 101(5):500-502.